article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
List view / Grid view
Pfizer
Filter the results
news
XTANDI® treatment granted priority review by FDA
XTANDI® sNDA seeks to add an indication for men with prostate cancer that's spread but is sensitive to hormone therapy.
news
Two lots of migraine medication have been recalled
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
article
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
news
FTC investigates contracts regarding autoimmune disease drug, Remicade
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
news
RUXIENCE™ biosimilar granted approval from FDA
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
news
FDA approves nine generics for Lyrica drug
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
news
Controlled release drug delivery market to rise 14.3 percent
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
news
NICE endorses dacomitinib for treatment of lung cancer
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
news
New analysis shows that 3,400 drug prices have risen in 2019 so far
The price of over 3400 drugs have been hiked in the first half of 2019, surpassing the number of hikes imposed during the same period last year.
article
The impact of counterfeit drugs in south and south-east Asia
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
news
Pfizer successfully completes the acquisition of Therachon
Pharmaceutical company, Pfizer, has announced it has completed the acquisition of Therachon for $340 million.
news
Former FDA Commissioner joins Pfizer’s board of directors
Former FDA Commissioner, Scott Gottlieb, who stepped down from the administration in April, has joined Pfizer’s board of directors.
news
Pharmaceutical company combats counterfeit Viagra
Pharmaceutical company Pfizer was able to target the distribution of counterfeit Viagra in Hong Kong through serialisation technology.
news
GSK reported to have started the sale of $1.2 billion consumer health drugs
According to Reuters, GSK has started the sale of some consumer health brands as it seeks to raise £1 billion.